WHO HIV drug resistance network steering group meeting report, June 2021

Overview

WHO HIV drug resistance network (HIVResNet) is a group composed of international experts, researchers, laboratorians, organizations, partners, stakeholders, and civil society members. HIVResNet has an important advisory role and implementation function in global efforts to prevent, monitor, and respond to HIV drug resistance. Governance of WHO HIVResNet is provided by its Steering Group, which also serves as the principal advisory body to WHO on HIV drug resistance.

The report summarizes deliberations of the virtual meeting of the WHO HIVResNet Steering Group held on 9 June 2021. Specifically, the reported summarizes the review of the 2020 progress presented by the secretariat (WHO) to the steering Group and deliberations and technical advice of the group on the planned content of WHO’s 2021 HIV drug resistance report, the targeted product profile (TPP) for HIV drug resistance testing proposal, the proposed joint WHO HIVResNet, Clinical Adult working group for Drug Optimization (CADO), and Paediatric working group on Drug Optimization (PADO) meeting, and strategic direction on updating the 2017-2021 five-year Global Action Plan on HIV drug resistance.